Cardinal Health Exec Says GLP-1 Drugs Are Continuing to Contribute to Revenue and "Grow More so Than We Had Originally Expected" - Conf Call
卡地納健康高管表示GLP-1藥物繼續爲營業收入做出貢獻,並且"增長超出我們最初的預期"-電話會議
Cardinal Health Exec Says GLP-1 Drugs Are Continuing to Contribute to Revenue and "Grow More so Than We Had Originally Expected" - Conf Call
卡地納健康高管表示GLP-1藥物繼續爲營業收入做出貢獻,並且"增長超出我們最初的預期"-電話會議
譯文內容由第三人軟體翻譯。